Molecular and Functional Characteristics of Proton-Coupled Folate Transporter

被引:31
作者
Yuasa, Hiroaki [1 ]
Inoue, Katsuhisa [1 ]
Hayashi, Yayoi [2 ]
机构
[1] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Mizuho Ku, Nagoya, Aichi 4678603, Japan
[2] Kinjo Gakuin Univ, Dept Biopharmaceut, Coll Pharm, Moriyama Ku, Nagoya, Aichi 4638521, Japan
关键词
intestinal absorption; active transport; membrane transporter; genomics; drug interaction; proton-coupled folate transporter; folate; methotrexate; sulfasalazine; CANCER RESISTANCE PROTEIN; MAMMALIAN-CELLS; RHEUMATOID-ARTHRITIS; CARRIER; SULFASALAZINE; METHOTREXATE; EXPRESSION; IDENTIFICATION; ABSORPTION; MOUSE;
D O I
10.1002/jps.21515
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Proton-coupled folate transporter (PCFT) has recently been identified as the molecular entity of the carrier-mediated intestinal folate transport system. PCFT has been demonstrated to be most abundantly expressed in the upper small intestine, localizing at the brush border membrane of epithelial cells, transport folate and its analogs more efficiently at lower (acidic) pH by a H(+)-coupled cotransport mechanism, and have a high affinity for folate with a Michaelis constant (K(m)) of a few mu M at pH 5.5 and somewhat lower affinities for reduced folates and methotrexate (MTX,). A loss of PCFT function due to a homozygous mutation in its gene has been indicated to be responsible for hereditary folate malabsorption. Thus, PCFT has all the characteristics of the brush border (1)H-coupled cotransporter for folate and analogs, which has long been suggested to be present in the intestine. Furthermore, sulfasalazine was found to be a potent inhibitor of PCFT, suggesting that it is a risk factor that would cause malabsorption of folate and also MTX, when coadministered in the treatment of rheumatoid arthritis. Understanding the molecular and functional characteristics of PCFT should be important and helpful in exploring therapeutic strategies for folate malabsorption and in optimizing therapies using antifolate drugs. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:1608-1616, 2009
引用
收藏
页码:1608 / 1616
页数:9
相关论文
共 34 条
[1]  
Chen ZS, 2003, CANCER RES, V63, P4048
[2]  
Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165
[3]  
DIXON KH, 1994, J BIOL CHEM, V269, P17
[4]   Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: Overlapping distribution with sulfotransferases [J].
Enokizono, Junichi ;
Kusuhara, Hiroyuki ;
Sugiyama, Yuichi .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (06) :922-928
[5]   Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis [J].
Haagsma, CJ ;
Blom, HJ ;
van Riel, PLCM ;
van't Hof, MA ;
Giesendorf, BAJ ;
van Oppenraaij-Emmerzaal, D ;
van de Putte, LBA .
ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (02) :79-84
[6]  
Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082
[7]   SULFASALAZINE INHIBITS THE ABSORPTION OF FOLATES IN ULCERATIVE-COLITIS [J].
HALSTED, CH ;
GANDHI, G ;
TAMURA, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (25) :1513-1517
[8]  
HEPNER GW, 1968, LANCET, V11, P302
[9]  
Hooijberg JH, 1999, CANCER RES, V59, P2532
[10]   Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model [J].
Inoue, Katsuhisa ;
Nakai, Yasuhiro ;
Ueda, Sayaka ;
Kamigaso, Shunsuke ;
Ohta, Kin-Ya ;
Hatakeyama, Mai ;
Hayashi, Yayoi ;
Otagiri, Masaki ;
Yuasa, Hiroaki .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2008, 294 (03) :G660-G668